CureVac Shareholders Face Pivotal Vote on BioNTech Acquisition

CureVac NL0015436031

The countdown has begun for CureVac’s final days as an independent publicly traded company. A special shareholder meeting scheduled for Tuesday, November 25, will determine the pharmaceutical company’s fate as it moves toward complete integration with BioNTech. Market activity already reflects the impending acquisition, with CureVac shares trading in near-perfect correlation with BioNTech’s stock movements, displaying no independent market drivers. The critical question remains whether the shareholder vote holds any potential for surprise outcomes or if the merger is effectively predetermined.